TherapeuticsMD, Inc. — Director's Dealing 2021

May 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2021-05-10

Reporting Person: Milligan John C.K. IV (Secretary/CEO of subsidiary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-10	Common Stock	M	103500	—	Acquired	1796955	Direct
2021-05-11	Common Stock	S	44252	$1.04	Disposed	1752703	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-10	Restricted Stock Units	$0	M	103500	Disposed		Common Stock (103500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3582373	Indirect

Footnotes

F1: On May 10, 2021, the reporting person received 103,500 shares of issuer common stock in settlement of restricted stock units (RSUs), which vested on March 30, 2021.

F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended.

F4: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement.

F5: The RSUs vest in three equal installments annually beginning March 30, 2021, becoming fully vested on March 30, 2023.